How Pharma Companies Can Benchmark R&D Performance: A Step-by-Step Guide to the Innovation and Invention Index

Overview

Every year, the consulting firm IDEA Pharma releases its much-anticipated Pharmaceutical Innovation & Invention Index, ranking top drugmakers on two critical dimensions of research and development effectiveness. In a recent landmark edition, Eli Lilly achieved an unprecedented feat: it ranked first in both categories simultaneously, outperforming peers like Pfizer, Novartis, and Roche. This guide will walk you through the methodology behind the index, how to interpret the rankings, and how your organization can apply these metrics to improve R&D performance. Whether you're a biotech executive, a strategy analyst, or a curious industry watcher, this tutorial will give you actionable insights into evaluating pharma R&D success.

By the end of this guide, you will understand:

• What the Innovation and Invention Index measures
• How each metric is calculated
• How to use the rankings for competitive benchmarking
• Common pitfalls to avoid when interpreting R&D performance data

Prerequisites

Before diving into the step-by-step analysis, ensure you have a baseline understanding of the pharmaceutical R&D landscape. Familiarity with concepts like clinical trial phases, regulatory approvals, and revenue attribution will help. No special software is needed, but access to IDEA Pharma’s public summaries (or a STAT+ subscription for full reports) is beneficial.

• Basic knowledge: Understanding of drug development pipeline stages (Phase 1–4, approval, launch)
• Data sources: IDEA Pharma’s annual report (available at IDEA Pharma website) or secondary analyses from industry publications
• Tools: Spreadsheet software for comparing metrics (optional)

Step-by-Step Instructions

Step 1: Understand the Two Ranking Categories

IDEA Pharma splits R&D performance into two distinct but complementary indices:

• Innovation Index: Measures the revenue contribution from new drugs launched in the past five years relative to total revenue. This indicates how effectively a company translates R&D investment into commercial success.
• Invention Index: Measures the breadth and depth of the pipeline—number of drugs in development, R&D spending, and patent activity. It reflects the capacity to generate novel candidates.

In 2024, Eli Lilly topped both, a first in the index’s history. Previously, companies like Roche or Novartis might lead one but lag in the other.

Step 2: Collect the Raw Data for Your Company

To replicate the analysis internally, gather the following data points for your organization and key competitors:

• For Innovation: Revenue from products launched in the last five years (from annual reports or SEC filings).
• For Invention: Total R&D expenditure, number of active clinical programs (Phase 1–3), number of New Molecular Entities (NMEs) in the pipeline, and patent filings.

Normalize values by company size (e.g., R&D spend as % of revenue) to allow fair comparisons.

Step 3: Calculate the Innovation Score

IDEA Pharma does not publish exact formulas, but a simplified approach is:

1. Sum the revenue from all drugs launched within the last five years.
2. Divide by total company revenue for the same period.
3. Multiply by a weighting factor that accounts for therapeutic area novelty (IDEA applies a proprietary modifier).

Example: If Lilly’s new drugs (e.g., tirzepatide) contributed $10B of $40B total revenue, the raw innovation ratio is 0.25. A high ratio indicates strong innovation.

Step 4: Calculate the Invention Score

Invention is a composite metric. A basic version includes:

• Number of drugs in Phase 2 or later (weighted more heavily)
• R&D spending as a multiple of industry average
• Patent applications per year

Combine these into a single normalized score (e.g., z-score) and rank companies. Lilly’s lead likely stems from a deep pipeline in GLP-1, oncology, and immunology, plus high R&D spend (~25% of revenue).

Step 5: Compare Your Scores Against the Benchmark

Plot your Innovation vs. Invention score in a 2×2 matrix:

• High Innovation, High Invention (e.g., Lilly) – ideal “dual leader”
• Low Innovation, High Invention – good pipeline but poor commercialization (e.g., some biotechs)
• High Innovation, Low Invention – strong market capture but thin pipeline (danger of future obsolescence)
• Low Innovation, Low Invention – lagging in both

Identify your quadrant and set strategic priorities accordingly.

Step 6: Apply Insights to R&D Strategy

• If invention is weak: increase early-stage investment, acquire promising assets, or form partnerships with academic labs.
• If innovation is weak: improve commercial execution, accelerate time-to-market, or refocus on higher-reward indications.

For example, after seeing its invention score drop, a mid-tier pharma might boost in-licensing of novel targets.

Common Mistakes

Mistake 1: Treating the Rankings as Absolute Truth

The index uses proprietary weighting and excludes factors like regulatory risk or manufacturing scale. A high rank does not guarantee future success. Always cross-reference with clinical trial outcomes and revenue forecasts.

Mistake 2: Ignoring the Time Lag

R&D investments take 10+ years to show up in innovation scores. A company cutting R&D today might see invention scores drop only years later, leading to a false sense of stability.

Mistake 3: Overemphasizing Revenue from New Drugs

Some blockbusters (e.g., Lilly’s Mounjaro) can skew innovation scores. A company could rank high with just one hit product while having a weak pipeline otherwise. Look at the pipeline diversity alongside the index.

Mistake 4: Comparing Companies of Vastly Different Sizes Without Normalization

Big pharma naturally has more revenue and pipeline. Always use ratios (e.g., R&D spend per dollar of sales) rather than absolute numbers.

Summary

IDEA Pharma’s Innovation and Invention Index offers a valuable framework for benchmarking a company’s R&D health. Eli Lilly’s double-first demonstrates the power of balancing both commercial success from recent launches (innovation) and a rich pipeline (invention). To use this guide effectively, collect your own data, compute simplified scores, and identify gaps. Avoid common errors like ignoring the long-term nature of R&D or relying on a single metric. With consistent monitoring, you can drive more strategic decisions and emulate the top performers.